Registry for assessing the effects of Upper Tract Urothelial Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a comprehensive registry for patients with Upper Tract Urothelial Cancer (UTUC) at Prince of Wales Hospital in Hong Kong. It will collect clinical information, treatment outcomes, and biological samples such as blood, urine, and tumor tissue to investigate new diagnostic and therapeutic agents. The goal is to better understand the epidemiology, natural history, and management of UTUC, addressing existing controversies and limitations in treatment approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male patients \> 18 years old
* Patients who has presence of UTUC and pending for surgery
* Patients who has history of UTUC with any intervention performed

Exclusion Criteria:

\- Patients fail to provide informed consent

Where it's running

• Prince of Wales Hospital
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Jeremy Yuen-Chun TEOH, FRCS(Ed) MBBS — Chinese University of Hong Kong
• Study coordinator: Jeremy Yuen-Chun TEOH, FRCS(Ed)
• Email: jeremyteoh@surgery.cuhk.edu.hk
• Phone: 3505-2625

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Specimen Collection for Validation of a New urine-based bladder cancer test

  This study collects urine and tumor samples from adults being evaluated or treated for urothelial cancer to validate a next‑generation sequencing platform.

  Recruiting Convergent Genomics, Inc. · Oceanside, California and 22 other locations · NCT07673016

• Robotic surgery for upper tract urothelial cancer patients

  This study tests whether using a special robotic system for kidney and ureter surgery can safely help patients with upper tract urothelial cancer recover better and have good outcomes.

  Recruiting National Taiwan University Hospital · Taipei · NCT06987552

• Sequential gemcitabine plus Jelmyto for favorable high-grade upper tract urothelial cancer

  This trial tests whether giving gemcitabine followed by Jelmyto directly into the kidney can control favorable high‑grade upper tract urothelial cancer and help people avoid kidney removal.

  Recruiting Phase 2 Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT06822010

• Examining gene alterations and chemotherapy response in advanced bladder cancer

  This study is testing if certain gene changes can help predict how well advanced bladder cancer patients will respond to platinum-based chemotherapy treatments.

  Recruiting Phase 4 Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT06820255

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• Blood test for detecting tumor DNA in bladder and upper tract cancer

  A blood test that looks for tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer is being tested to see if it matches what’s found in tumor tissue and if it can help track recurrence or remission over two years.

  Recruiting AZ Sint-Lucas Gent · Ghent, East Flanders · NCT07756437

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.